---
title: "3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292245263.md"
description: "Analysts highlight three under-$10 stocks with strong upside potential: AbCellera Biologics (ABCL), Serve Robotics (SERV), and Nuvation Bio (NUVB). ABCL, focused on AI-driven drug discovery, holds a Strong Buy consensus with an average price target of $9.40, implying nearly 29% upside. These low-priced growth names are tied to fast-moving sectors like autonomous delivery and advanced cancer therapy, though they carry higher risk."
datetime: "2026-07-09T21:29:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292245263.md)
  - [en](https://longbridge.com/en/news/292245263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292245263.md)
generator: "portal-rs"
---

# 3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

Some early-stage growth names now sit in the under-$10 range, such as AbCellera Biologics (ABCL), Serve Robotics (SERV), and Nuvation Bio (NUVB). These low-priced stocks carry risk, but each is tied to fast‑moving sectors, such as AI‑driven drug discovery, autonomous delivery, and advanced cancer therapy. Let's take a closer look at the three stocks worth watching this week.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

## **1\. AbCellera (ABCL)**

Biotechnology company AbCellera is gaining attention due to its push into AI‑powered antibody discovery. The firm partners with major drugmakers to speed up early-stage biologics development, using machine learning tools to search, design, and optimize antibody candidates. Also, AbCellera's platform gives it an edge as drugmakers look for faster and cheaper ways to build new therapies.

On TipRanks, analysts have a Strong Buy consensus rating on ABCL stock based on six Buys assigned in the past three months. Further, the average AbCellera stock price target of $9.40 per share implies 28.94% upside potential.

### Related Stocks

- [SERV.US](https://longbridge.com/en/quote/SERV.US.md)
- [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md)
- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)
- [NUVB+.US](https://longbridge.com/en/quote/NUVB+.US.md)

## Related News & Research

- [AbCellera to present at Cantor Global Healthcare Conference](https://longbridge.com/en/news/297823858.md)
- [ABCL: Major TCE deals and strong liquidity position support robust pipeline advancement](https://longbridge.com/en/news/295026877.md)
- [MAZE: Promising phase II results in AMKD and PKU, with pivotal trials and key data readouts ahead](https://longbridge.com/en/news/298476154.md)
- [Sino Biopharm CEO Tse says AI, internationalization anchor counter-cyclical growth strategy](https://longbridge.com/en/news/298258012.md)
- [CRMD: Strong revenue growth, pipeline expansion, and financial flexibility drive continued value creation](https://longbridge.com/en/news/298461323.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**